<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03340766</url>
  </required_header>
  <id_info>
    <org_study_id>20150290</org_study_id>
    <secondary_id>2016-002191-27</secondary_id>
    <nct_id>NCT03340766</nct_id>
  </id_info>
  <brief_title>Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab (KEYNOTE-348)</brief_title>
  <official_title>A Phase 1b Open Label Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adult Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL) (KEYNOTE-348)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amgen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Amgen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase 1b: To determine the maximum tolerated dose (MTD) of blinatumomab in combination with
      pembrolizumab in adult subjects with relapsed or refractory (r/r) DLBCL
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 16, 2018</start_date>
  <completion_date type="Anticipated">November 1, 2025</completion_date>
  <primary_completion_date type="Anticipated">December 28, 2021</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>Yes</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of dose limiting toxicities (DLTs)</measure>
    <time_frame>Up to study day 63, depending on cohort dosing and schedule</time_frame>
    <description>Incidence of dose limiting toxicities (DLTs) will be assessed during each cohort</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective Response</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Objective response (OR) (including CR and PR) by the Lugano Classification (Cheson et al, 2014) and Revised Response Criteria (Cheson et al, 2007)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Progression Free Survival (PFS) by Cheson Criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>Subjects followed for survival up to 48 months (24 months after last dose of pembrolizumab)</time_frame>
    <description>Overall Survival (OS) will be determined for 24 months following the last dose of pembrolizumab.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Duration of response (DOR) for subjects with OR (ie, CR and partial remission [PR]) by the Lugano Classification (Cheson et al, 2014)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinatumomab Steady state concentration</measure>
    <time_frame>Up to study day 43, depending on cohort dosing and schedule</time_frame>
    <description>Pharmacokinetic profile of Blinatumomab: Steady state concentration (Css)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Blinatumomab Clearance rate</measure>
    <time_frame>Up to study day 43, depending on cohort dosing and schedule</time_frame>
    <description>Pharmacokinetic profile of Blinatumomab - Clearance rate</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembrolizumab Peak Plasma Concentration</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Pembrolizumab Pharmacokinetic parameter: Peak Plasma Concentration (Cmx)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembrolizumab Minimum plasma concentration</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Pharmacokinetic profile of Pembrolizumab: Minumum plasma concentration (Cmn)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pembrolizumab PK Parameter - AUC</measure>
    <time_frame>Up to 25 months</time_frame>
    <description>Pharmacokinetic profile of Pembrolizumab: Area under the plasma concentration versus time curve (AUC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete response</measure>
    <time_frame>Study week 10 and every 12 weeks thereafter, for up to 24 months</time_frame>
    <description>Complete response (CR) by Lugano Classification (Cheson et al, 2014) and Revised Response Criteria (Cheson et al, 2007)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL)</condition>
  <arm_group>
    <arm_group_label>COHORT Ia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 microgram plus Pembrolizumab (day 15).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT IIa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 to 56 microgram plus Pembrolizumab (day 19).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>COHORT IIIa</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Blinatumomab 9 to 28 to 112 microgram plus Pembrolizumab (day 19).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>This cohort will test the Maximum Tolerated Dose of Blinatumomab in combination with Pembrolizumab identified using cohort design from cohorts Ia, IIa, and IIIa tested in Part 1 of the study.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Blinatumomab</intervention_name>
    <description>Up to 2 cycles of Blinatumomab may be given, where cycle 1 lasts 8 weeks, and cycle 2 lasts 28 days. The treatment is given as a continuous intravenous infusion. The dosing given is dependent on the cohort, and is as follows:
Cohort Ia: 9 microgram/day for 7 days followed by 28 microgram/day for the remainder of each cycle.
Cohort IIa: 9 microgram/day for 7 days followed by 28 microgram/day for 7 days followed by 56 microgram/day for the remainder of each cycle.
Cohort IIIa: 9 microgram/day for 7 days followed by 28 microgram/day for 7 days followed by 112 microgram/day for the remainder of each cycle.
The Maximum Tolerated Dose identified through this cohort design will then be tested in the expansion cohort.</description>
    <arm_group_label>COHORT IIIa</arm_group_label>
    <arm_group_label>COHORT IIa</arm_group_label>
    <arm_group_label>COHORT Ia</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>Blincyto</other_name>
    <other_name>AMG 103</other_name>
    <other_name>Formerly known as MT103 or bscCD19xCD3</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>One cycle of Pembrolizumab is a 200 milligrams intravenous injection lasting 30 minutes. One cycle will be given every 3 weeks until disease progression, or for a maximum of 35 cycles.
Treatment start is dependent on the cohort:
Cohort Ia: Study day 15 (where blinatumomab treatment started on study day 1) Cohort IIa, IIIa: Study day 19 (where blinatumomab treatment stated on study day 1)</description>
    <arm_group_label>COHORT IIIa</arm_group_label>
    <arm_group_label>COHORT IIa</arm_group_label>
    <arm_group_label>COHORT Ia</arm_group_label>
    <arm_group_label>Expansion Cohort</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have histologically confirmed Diffuse Large B-Cell Lymphoma that is either:

          -  Refractory after at least one regimen of systemic chemotherapy and/or targeted
             therapy, or

          -  In first or later relapse if have received at least 2 systemic regimens since time of
             diagnosis, or

          -  Relapsed post-autologous or allogeneic HSCT with adequate organ function after
             proximity to transplantation time exclusions as specified in Exclusion Criteria 208
             and 209

          -  Have measureable disease

          -  Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2

          -  Life expectancy of ≥ 12 weeks in the opinion of the Investigator

          -  Biopsy proven DLBCL (biopsy proven at least at primary diagnosis of DLBCL)

        Other Inclusion Criteria May Apply

        Exclusion Criteria:

          -  Richter's transformation (DLBCL arising in the setting of prior chronic lymphocytic
             leukemia) or Primary Mediastinal B cell Lymphoma (PMBCL)

          -  History or presence of clinically relevant Central Nervous System pathology such as
             epilepsy, paresis, aphasia, stroke, severe brain injury, dementia, Parkinson's
             disease, cerebellar disease, organic brain syndrome, or psychosis.

          -  Has a diagnosis of immunodeficiency or has received systemic steroid therapy (in
             excess of 10 mg daily of prednisone equivalent) or any other form of immunosuppressive
             therapy within 7 days prior to the first dose of protocol specified therapy.

          -  Has undergone prior allogeneic HSCT:

               -  within the last 5 years OR

               -  greater than 5 years ago but has active graft versus host disease (GvHD)
                  requiring systemic treatment.

          -  Has received autologous HSCT within 6 weeks prior to start of treatment.

        Other Exclusion Criteria May Apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>MD</last_name>
    <role>Study Director</role>
    <affiliation>Amgen</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Amgen Call Center</last_name>
    <phone>866-572-6436</phone>
    <email>medinfo@amgen.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0960</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29424</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Greenville</city>
        <state>South Carolina</state>
        <zip>29607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Darlinghurst</city>
        <state>New South Wales</state>
        <zip>2010</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <zip>2065</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Adelaide</city>
        <state>South Australia</state>
        <zip>5000</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>East Melbourne</city>
        <state>Victoria</state>
        <zip>3002</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Geelong</city>
        <state>Victoria</state>
        <zip>3220</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Murdoch</city>
        <state>Western Australia</state>
        <zip>6150</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Créteil Cedex</city>
        <zip>94010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Nantes Cedex 1</city>
        <zip>44035</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Pierre Benite Cedex</city>
        <zip>69495</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Ulm</city>
        <zip>89081</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Würzburg</city>
        <zip>97080</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015 CN</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Santander</city>
        <state>Cantabria</state>
        <zip>39008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Salamanca</city>
        <state>Castilla León</state>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Barcelona</city>
        <state>Cataluña</state>
        <zip>08025</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>France</country>
    <country>Germany</country>
    <country>Netherlands</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.amgentrials.com</url>
    <description>AmgenTrials clinical trials website</description>
  </link>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>October 23, 2017</study_first_submitted>
  <study_first_submitted_qc>November 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">November 14, 2017</study_first_posted>
  <last_update_submitted>July 7, 2020</last_update_submitted>
  <last_update_submitted_qc>July 7, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL Relapsed post-autologous or allogeneic hematopoietic stem cell transplantation (HSCT)</keyword>
  <keyword>Antibodies</keyword>
  <keyword>Bispecific in combination with PD-1/PD-L1 inhibitor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
    <mesh_term>Blinatumomab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>De-identified individual patient data for variables necessary to address the specific research question in an approved data sharing request.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Data sharing requests relating to this study will be considered beginning 18 months after the study has ended and either 1) the product and indication (or other new use) have been granted marketing authorization in both the US and Europe or 2) clinical development for the product and/or indication discontinues and the data will not be submitted to regulatory authorities. There is no end date for eligibility to submit a data sharing request for this study.</ipd_time_frame>
    <ipd_access_criteria>Qualified researchers may submit a request containing the research objectives, the Amgen product(s) and Amgen study/studies in scope, endpoints/outcomes of interest, statistical analysis plan, data requirements, publication plan, and qualifications of the researcher(s). In general, Amgen does not grant external requests for individual patient data for the purpose of re-evaluating safety and efficacy issues already addressed in the product labelling. Requests are reviewed by a committee of internal advisors, and if not approved, may be further arbitrated by a Data Sharing Independent Review Panel. Upon approval, information necessary to address the research question will be provided under the terms of a data sharing agreement. This may include anonymized individual patient data and/or available supporting documents, containing fragments of analysis code where provided in analysis specifications. Further details are available at the URL below.</ipd_access_criteria>
    <ipd_url>https://www.amgen.com/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

